Antibody Drug Conjugates: Contract Manufacturing Market to Evolve Rapidly, Predicts Roots Analysis

Chandigarh, India, June 28, 2015 --(PR.com)-- Roots Analysis has announced addition of the “Antibody Drug Conjugates: Contract Manufacturing Market 2014-2024” report to their offering. The report provides an extensive study of the contract manufacturing opportunity for this emerging class of therapeutics. It identifies various CMOs active in this space, their capabilities with respect to ADCs, available capacity (clinical/commercial) for bio-conjugation and geographic location/spread of the facilities.

Shivani Singh, the principal analyst, said, “The multi-component aspect of ADCs deems it necessary to have both biologic and high-potency facilities. Despite the fact that this new class of therapeutic agents is gaining increased attention, in-house manufacturing of these molecules is rare.

“Most of the companies have limited number of ADCs under development. Considering that utilisation rates are likely to be low in near future, the investment required for setting up in-house high-containment biologic facilities is a huge financial risk. As such, majority of the work is currently being outsourced.”

The report examines insights gathered from secondary research and/or interviews of over 100 companies. Examples of companies which were interviewed include:

Piramal Healthcare
Lonza
Catalent
BSP Pharmaceuticals

There has been a surge in investments from CMOs for facility expansions during the last one year. Although, there are only three marketed ADCs till date (including Mylotarg), a rich and growing pipeline offers a bigopportunity for contract manufacturers. Roots Analysis predicts that the size of this opportunity is likely to be more than USD 1 billion in near future. The detailed market forecast is based on the analysis of:

ADC therapeutics pipeline
In-house/contract manufacturing status of phase II, phase III and marketed ADCs
Commercial sales potential of molecules under development
Likely outsourcing profile across various steps involved in manufacturing

Who will benefit from this report?
This research is targeted towards pharma companies and CMOs working in the field of ADCs. In particular, you could benefit if you are an:

Investor
Contract manufacturer
R&D Manager
Business Intelligence / Scientific Analyst
Licensing / Portfolio Manager
Strategy Manager

For additional details and/or to request sample pages, please visit the website.

The company had done another comprehensive research project on the ADC market in 2013. The details of this study can be found on the company's website.

About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.